0.00
price down icon100.00%   -0.2075
 
loading
Precedente Chiudi:
$0.2075
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$4.26M
Reddito:
$31.56M
Utile/perdita netta:
$-46.89M
Rapporto P/E:
0.00
EPS:
-3.0329
Flusso di cassa netto:
$-26.70M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
Value
$0.00
$0.00
Intervallo di 1 settimana:
Value
$0.00
$0.00
Portata 52W:
Value
$0.00
$3.09

Casi Pharmaceuticals Inc Stock (CASI) Company Profile

Name
Nome
Casi Pharmaceuticals Inc
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
233
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-14
Name
Ultimi documenti SEC
Name
CASI's Discussions on Twitter

Compare CASI vs VRTX, REGN, ARGX, ALNY, ONC

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CASI
Casi Pharmaceuticals Inc
0.00 4.26M 31.56M -46.89M -26.70M -3.0329
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.38 125.08B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
774.66 81.90B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
728.09 45.06B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.43 42.50B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
298.91 33.16B 5.36B 287.73M 924.18M 2.5229

Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-05-18 Iniziato BTIG Research Buy
2021-04-26 Iniziato Mizuho Buy
2020-10-23 Iniziato Oppenheimer Outperform
2016-09-22 Iniziato Maxim Group Buy
2015-10-29 Ripresa H.C. Wainwright Buy
2015-06-23 Iniziato H.C. Wainwright Buy
Mostra tutto

Casi Pharmaceuticals Inc Borsa (CASI) Ultime notizie

pulisher
Mar 06, 2026

Short Squeeze: Can CASI Pharmaceuticals Inc deliver consistent EPS growth2025 Valuation Update & Daily Stock Momentum Reports - baoquankhu1.vn

Mar 06, 2026
pulisher
Mar 04, 2026

CASI Pharmaceuticals Inc. (CASIF) Price To Cash Flow - Zacks Investment Research

Mar 04, 2026
pulisher
Mar 04, 2026

CASI Pharmaceuticals Inc. (CASIF) Total Liabilities - Zacks Investment Research

Mar 04, 2026
pulisher
Mar 04, 2026

CASI Pharmaceuticals Inc. (CASIF) Return On Equity (TTM) - Zacks Investment Research

Mar 04, 2026
pulisher
Mar 04, 2026

CASI Pharmaceuticals Inc. (CASIF) Total Long Term Debt (Quarterly) - Zacks Investment Research

Mar 04, 2026
pulisher
Mar 04, 2026

CASI Pharmaceuticals Inc. (CASIF) Enterprise Value - Zacks Investment Research

Mar 04, 2026
pulisher
Mar 04, 2026

CASI Pharmaceuticals Inc. (CASIF) Total Expenses (Quarterly) - Zacks Investment Research

Mar 04, 2026
pulisher
Mar 04, 2026

CASI Pharmaceuticals Inc. (CASIF) Book Value - Zacks Investment Research

Mar 04, 2026
pulisher
Mar 03, 2026

CASI PHARMACEUTICALS INC (CASIF.US) Income Statements, Balance Sheet & Cashflow - Longbridge

Mar 03, 2026
pulisher
Mar 03, 2026

CASI PHARMACEUTICALS INC (CASIF.US) Latest News & Headlines - Longbridge

Mar 03, 2026
pulisher
Mar 03, 2026

CASI Pharmaceuticals, Inc.: Financial Data Forecasts Estimates and Expectations | CASIF | KYG1933S1012 - marketscreener.com

Mar 03, 2026
pulisher
Mar 03, 2026

CASI Pharmaceuticals, Inc.: Target Price Consensus and Analysts Recommendations | CASIF | KYG1933S1012 - marketscreener.com

Mar 03, 2026
pulisher
Mar 03, 2026

CASI Pharmaceuticals, Inc.: Revenue and Earnings Analysts Forecasts Revisions | CASIF | KYG1933S1012 - marketscreener.com

Mar 03, 2026
pulisher
Mar 03, 2026

Casi Pharmaceuticals CEO David Cory to step down at end of March - Investing.com

Mar 03, 2026
pulisher
Mar 03, 2026

CASI Pharmaceuticals CEO David Cory to Step Down; Executive Chairman Wei-Wu He Assumes Top Role - TipRanks

Mar 03, 2026
pulisher
Mar 03, 2026

Leadership change at CASI Pharmaceuticals (NASDAQ: CASI) as CEO exits - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

CASI Pharmaceuticals Inc. (CASIF) Gross Margin (TTM) - Zacks Investment Research

Mar 03, 2026
pulisher
Mar 02, 2026

CASI Pharmaceuticals Inc. (CASIF) Debt Equity Ratio (Quarterly) - Zacks Investment Research

Mar 02, 2026
pulisher
Mar 02, 2026

CASI Pharmaceuticals Inc. (CASIF) - Zacks Investment Research

Mar 02, 2026
pulisher
Mar 02, 2026

CASI Pharmaceuticals Inc. (CASIF) Price Book Value - Zacks Investment Research

Mar 02, 2026
pulisher
Mar 02, 2026

CASI Pharmaceuticals Inc. (CASIF) Cash From Operations (TTM) - Zacks Investment Research

Mar 02, 2026
pulisher
Mar 02, 2026

CASIF (CASI Pharmaceuticals) PB Ratio : (As of Mar. 02, 2026) - GuruFocus

Mar 02, 2026
pulisher
Feb 28, 2026

CASI Pharmaceuticals Inc. (CASIF) Return On Assets (TTM) - Zacks Investment Research

Feb 28, 2026
pulisher
Feb 28, 2026

Net debt of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 28, 2026
pulisher
Feb 28, 2026

CASI Pharmaceuticals Inc. (CASIF) Earnings Yield (TTM) - Zacks Investment Research

Feb 28, 2026
pulisher
Feb 28, 2026

EBIT per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 28, 2026
pulisher
Feb 28, 2026

EBITDA margin % of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 28, 2026
pulisher
Feb 28, 2026

After tax other income/expense of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 28, 2026
pulisher
Feb 28, 2026

Long term debt to total equity ratio of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 28, 2026
pulisher
Feb 28, 2026

Operating expenses (excl. COGS) of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 28, 2026
pulisher
Feb 28, 2026

CapEx per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 28, 2026
pulisher
Feb 28, 2026

Net current asset value per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 28, 2026
pulisher
Feb 28, 2026

Preferred dividends of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 28, 2026
pulisher
Feb 28, 2026

Enterprise value to EBITDA ratio of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 28, 2026
pulisher
Feb 28, 2026

Working capital per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 28, 2026
pulisher
Feb 28, 2026

Total debt of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 28, 2026
pulisher
Feb 28, 2026

Free cash flow per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 28, 2026
pulisher
Feb 28, 2026

Total debt per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 28, 2026
pulisher
Feb 27, 2026

CASI Pharmaceuticals, Inc. Balance Sheet – OTC:CASIF - TradingView

Feb 27, 2026
pulisher
Feb 27, 2026

Technical Analysis of CASI Pharmaceuticals, Inc. (OTC:CASIF) - TradingView

Feb 27, 2026
pulisher
Feb 27, 2026

CASI Pharmaceuticals Inc. (CASIF) Revenue (Quarterly) Yoy Growth - Zacks Investment Research

Feb 27, 2026
pulisher
Feb 27, 2026

CASI Pharmaceuticals Inc. (CASIF) Total Expenses (TTM) - Zacks Investment Research

Feb 27, 2026
pulisher
Feb 27, 2026

Diluted shares outstanding of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 27, 2026
pulisher
Feb 27, 2026

Gross profit of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 27, 2026
pulisher
Feb 27, 2026

EBIT of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 27, 2026
pulisher
Feb 27, 2026

Dilution adjustment of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 27, 2026
pulisher
Feb 27, 2026

Non-controlling/minority interest of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 27, 2026
pulisher
Feb 27, 2026

Free cash flow of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 27, 2026
pulisher
Feb 27, 2026

CASI Pharmaceuticals, Inc. Statistics – OTC:CASIF - TradingView

Feb 27, 2026
pulisher
Feb 27, 2026

EBITDA of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 27, 2026
pulisher
Feb 27, 2026

Pretax income of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Feb 27, 2026

Casi Pharmaceuticals Inc Azioni (CASI) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$46.69
price up icon 1.57%
$29.58
price down icon 0.40%
$55.97
price up icon 1.80%
$90.84
price up icon 8.28%
$139.40
price down icon 3.09%
biotechnology ONC
$298.91
price down icon 2.12%
Capitalizzazione:     |  Volume (24 ore):